NASDAQ : CADL
Candel Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 8.65 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 661.89M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 637.40M |
| Enterprise Value | 485.35M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 76.52M |
| Shares Outstanding | 76.52M |
| Shares Change (YoY) | +45.29% |
| Shares Change (QoQ) | +18.87% |
| Owned by Insiders (%) | 7.57% |
| Owned by Institutions (%) | 58.86% |
| Float | 60.22M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 257.02 |
| PB Ratio | 5.03 |
| P/TBV Ratio | 5.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 16.09 |
| Quick Ratio | 15.89 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.26 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -81.84% |
| Return on Assets (ROA) | -28.64% |
| Return on Invested Capital (ROIC) | -32.81% |
| Return on Capital Employed (ROCE) | -36.83% |
| Weighted Average Cost of Capital (WACC) | 2.89% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.61M |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.31 |
| 52-Week Price Change | +51.73% |
| 50-Day Moving Average | 10.68 |
| 200-Day Moving Average | 8.28 |
| Relative Strength Index (RSI) | 37.70 |
| Average Volume (20 Days) | 953,356 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 12.77M |
| Short Previous Month | 13.00M |
| Short % of Shares Out | 16.69% |
| Short % of Float | 21.21% |
| Short Ratio (days to cover) | 12.22 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -71.98M |
| Pretax Income | -88.53M |
| Net Income | -88.53M |
| EBITDA | -71.30M |
| EBIT | -71.98M |
| Earnings Per Share (EPS) | -$1.44 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 201.57M |
| Total Debt | 49.52M |
| Net Cash | 152.05M |
| Net Cash Per Share | $1.99 |
| Equity (Book Value) | 126.13M |
| Book Value Per Share | 1.66 |
| Working Capital | 191.47M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -56.02M |
| Capital Expenditures | -1.30M |
| Depreciation & Amortization | 678,000 |
| Net Borrowing | 41.21M |
| Free Cash Flow | -57.32M |
| FCF Per Share | -$0.75 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -45.29% |
| Shareholder Yield | -45.29% |
| Earnings Yield | -17.27% |
| FCF Yield | -8.99% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $22.11 |
| Price Target Difference | 165.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |